Last reviewed · How we verify
REMDESIVIR
At a glance
| Generic name | REMDESIVIR |
|---|---|
| Drug class | SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2020 |
Approved indications
Common side effects
- Nausea
- ALT increased
- AST increased
Key clinical trials
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
- Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections
- A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised (PHASE3)
- Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals (PHASE2)
- OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial (PHASE2)
- An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID. (PHASE4)
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) (PHASE2)
- OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- REMDESIVIR CI brief — competitive landscape report
- REMDESIVIR updates RSS · CI watch RSS